For the latest COVID-19 campus news and resources, visit umassmed.edu/coronavirus.

Search the Cancer Center site

Search the Cancer Center site

Home
About
About

Located in Worcester, Massachusetts, the UMass Cancer Center is committed to providing exceptional patient care, conducting cutting-edge research at the highest level, offering excellence in education and training, and serving as an educational resource and advocate for the Central Massachusetts community.
For Patients
For Patients

Expert Cancer Care in Central Massachusetts

We offer comprehensive cancer care for all childhood and adult cancers, combining state-of-the-art treatments with compassionate support for patients and their families.
Our Clinicians
Our Research
Our Research

Cutting-Edge Cancer Research

We carry out front-line research in basic, translational, clinical and population-based discovery to find newer, better methods for the prevention, detection, diagnosis, and treatment of cancer.
Education
Education

World Class Medical and Scientific Education

The UMass Cancer Center is dedicated to training the next generation of cancer researchers, clinicians and physician-scientists.
Outreach

Additional Resources

Beth A. McCormick, PhD

Professor and Vice Chair, Department of Microbiology and Physiological Systems; Worcester Foundation for Biomedical Research Chair II; Founder and Director, Center for Microbiome Research, UMass Chan Medical School

Website

Page Menu

Beth A. McCormick, PhD

Research Focus - Microbial-Based Cancer Therapy

Advancing preclinical development of novel microbial-based anticancer therapeutic agents
Investigating the interplay between microbes, tumors, and the immune system
Developing next-generation microbial therapeutics for multidrug resistance

Representative Publication

Mercado-Lubo R, Zhang Y, Zhao L, et al. A Salmonella nanoparticle mimic overcomes multidrug resistance in tumors. Nat Commun. 2016;7:12225

Read Publication

More Publications

In the News

Getting Results…

Research News

New study of oral therapy candidate indicates positive results for patients with mild-to-moderate COVID-19

New research by Kaleido Biosciences, Inc., and UMass Medical School’s John P. Haran, MD, PhD, and Beth McCormick, PhD, shows that the company’s microbiome metabolic therapy candidate produced positive results in patients with mild-to-moderate COVID-19.

Read more
Research News

Novel therapeutic, based on UMMS microbiome discoveries and licensed by Bacainn Therapeutics, targets ulcerative colitis

Discoveries made by Beth McCormick, PhD, and licensed by Bacainn Therapeutics, Inc. are heading to Phase I clinical trials for ulcerative colitis and other diseases associated with uncontrolled inflammation in the gut.

Read more